Ready to find a way to help outsmart your diabetes? The Guardian™ Connect CGM1 evaluation program allows you to try out the Guardian™ Connect CGM1 system for $0 out-of-pocket for 30-days.
We will start the process of determining your insurance or pharmacy coverage. A member of our team will reach to you about your eligibility. If you have questions please contact us at 1-888-882-8602 (M-F 9AM-6PM CT).
Only the Guardian™ Connect CGM alerts an hour in advance of both highs and lows.1 The Guardian™ Connect system detected up to 90.5% of lows without predictive alerts turned on and 98.5% of lows with the help of predictive alerts.2,3
The Guardian™ Connect system provides real-time readings with sensor glucose data transmitted to your compatible smartphone every 5 minutes. You’ll see your current sensor glucose and trend direction including predictive and threshold alerts in the palm of your hand. You can also receive discrete notifications from your compatible smart watch.
The Guardian™ Sensor 3 is our most accurate sensor— the same sensor that powers our hybrid closed-loop insulin pump system. It connects to the transmitter which sends sensor data via Bluetooth®* to your compatible smartphone.
Only Medtronic CGM enables you to set a higher volume alert for nighttime lows or mute alerts for daytime events. “Max Volume at Night” is an exclusive feature available with the Guardian™ Connect system.
It is easier than ever to share data with your care partner or healthcare provider with automatic uploads to CareLink™ Personal software. You customize who can view your glucose data and receive text alerts.
The Sugar.IQ™ app supercharges the Guardian™ Connect system by giving a big picture view of glucose patterns and the factors that affect them. Sugar.IQ™ app is only for iOS/Apple customers.
We check your insurance and pharmacy benefits for coverage. You choose the one that is best for you.
We have your back. Our 24-Hour Technical Support is staffed 24/7.
Our team of dedicated clinicians will help guide you through training and ongoing support, our goal is that you StartRight™.
Peace of mind: we’ll replace your device. See conditions.
No regrets: if you’re not happy with our product, you can return it within 30-days – no questions asked.
1. The system is intended to compliment, not replace, information obtained from standard blood glucose monitoring devices. All
therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices. All therapy
adjustments should be based on measurements obtained using a home blood glucose meter and not on values provided by the
2. Guardian™ Connect system SSED, page 19, Table 5. 90.5% Glucose Correct Detection Rate without Predictive Alerts at both 15 and 30 minutes when worn on the abdomen.
3. Guardian™ Connect system SSED, page 19, Table 5. 98.5% Glucose Correct Detection Rate based on Predictive Alerts at 30 minutes when worn on the abdomen.
* The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.
Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement , not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide and important safety information.
Important Safety Information: Sugar.IQ™ App
The Sugar.IQ™ app (MMT-8100) helps manage diabetes by facilitating the logging and display of meal entries and sensor glucose (SG) data, tracking meal log entries, reporting insights of how meals affect glucose levels, and supporting good choices and trends with motivational messages. The app serves as an additional display for real-time CGM data from the Guardian™ Connect system through the CareLink™ Personal software. It is not intended to provide medical advice and should not be relied upon for such purpose. The app is not intended to replace the real-time display of the CGM data on the Guardian™ Connect app, control any functions of the connecting device, calculate insulin or other drug doses, or modify date or control functions of the Guardia n™ Connect system. All therapy decisions should be made by the app user based on blood glucose (BG) measurements obtained from a BG meter. Changes to treatment should only be made in consultation with a healthcare professional (HCP). For complete details, consult the user guide and important safety information.
The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.
Important Safety Information: CareLink™ Software
The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult important saf ety information. and the appropriate CareLink™ User Guide.